Clinical | Mechanistic |
---|---|
Comparative efficacy of belimumab with different background immunosuppressive therapies | Secondary therapeutic effects of BAFF inhibition beyond primary effects on B cells |
Belimumab utility in unstudied patient populations (pediatric lupus, nephritis, cerebritis) | Effect of BAFF inhibition on selection and maturation of naïve and antigen-activated autoreactive B cells in humans |
Duration of therapeutic effect | Â |
Safety of belimumab post B-cell depletion | Â |
Utility of atacicept, LY2127399, and other BAFF/APRIL-blocking therapies for SLE and other autoimmune diseases | Â |